Hubbry Logo
Bausch HealthBausch HealthMain
Open search
Bausch Health
Community hub
Bausch Health
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Bausch Health
Bausch Health
Bausch Health
View on Wikipedia
from Wikipedia

Bausch Health Companies Inc. (formerly Valeant and ICN Pharmaceuticals) is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic pharmaceuticals, and over-the-counter products directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America.[3]

Key Information

History

[edit]

1959–2002: the Panić years

[edit]
Milan Panić founded ICN Pharmaceuticals in 1959.

In 1959, Milan Panić founded ICN Pharmaceuticals (International Chemical and Nuclear Corporation) in his Pasadena garage. Panić ran the company for 43 years, during which ICN established a foothold in the industry by acquiring niche pharmaceuticals and through the development of Ribavirin, an antiviral drug that became the standard treatment for hepatitis C.[4]

In 1994, ICN merged with SPI Pharmaceuticals Inc., Viratek Inc., and ICN Biomedicals Inc.[5]

On June 12, 2002, Panić stepped down from his position.[6]

2002–2010: Rebranding as Valeant

[edit]

In 2003, ICN changed its name to Valeant Pharmaceuticals.[7] In 2006, the company received approval in the U.S. to market Cesamet (nabilone), a synthetic cannabinoid.[8] The company also acquired the European rights to the drug for $14 million.[9]

In 2008, the Swedish pharmaceutical company Meda AB bought Western and Eastern Europe branches from Valeant for $392 million.[10] In September 2008, Valeant acquired Coria Laboratories for $95 million.[11] In November 2008, Valeant acquired DermaTech for $12.6 million.[12]

In January 2009, Valeant acquired Dow Pharmaceutical Sciences for $285 million.[13] In July 2009, Valeant announced its acquisition of Tecnofarma, a Mexican generic drug company.[14] In December 2009, Valeant announced its Canadian subsidiary would acquire Laboratoire Dr. Renaud, for C$23 million.[15]

In March 2010, Valeant announced its acquisition of a Brazilian generics and over-the-counter company for $28 million and manufacturing plant for a further $28 million.[16] In April 2010, Valeant announced that its Canadian subsidiary would acquire Vital Science Corp. for C$10.5 million.[17] In May 2010, Valeant acquired Aton Pharmaceuticals for $318 million.[18][19]

2010–2016: the Pearson years

[edit]

On September 28, 2010, Valeant merged with Biovail. The company retained the Valeant name and J. Michael Pearson as CEO, but was incorporated in Canada and temporarily kept Biovail's headquarters.[20][21] Setting on a path of aggressive acquisitions, Pearson ultimately turned Valeant into a platform company that grows by systematically acquiring other companies.

In February 2011, Valeant acquired PharmaSwiss S.A. for €350 million.[22] In July 2011, Valeant acquired Ortho Dermatologics from Janssen Pharmaceuticals for $345 million. The acquisition included the products Retin-A Micro, Ertaczo, and Renova, also known as tretinoin.[23] In August 2011, Valeant acquired 87.2% of the outstanding shares of Sanitas Group for €314 million.[24] In December 2011, Valeant acquired iNova Pharmaceuticals for A$625 million from Australian private equity firms Archer Capital with additional milestone payments of up to A$75 million.[25] In December 2011, Valeant acquired Dermik, a dermatology unit of Sanofi.[26]

In January 2012, Valeant acquired Brazilian sports nutrition company Probiotica for R$150 million.[27] In February 2012, Valeant acquired ophthalmic biotechnology company Eyetech Inc.[28] In April 2012, Valeant acquired Pedinol.[29] In April 2012, Valeant acquired assets from Atlantis Pharma in Mexico for $71 million.[30] In May 2012, Valeant acquired AcneFree for $64 million plus milestone payments.[31] In June 2012, Valeant acquired OraPharma for approximately $312 million with up to $144 million being paid in milestone payments.[32] In August 2012, Valeant agreed to buy skin-care company Medicis Pharmaceutical for $2.6 billion.[33][34] In January 2013, Valeant acquired the Russian company Natur Produkt for $163 million.[35] In March 2013, Valeant acquired Obagi Medical Products, Inc.[36]

In May 2013, the company acquired Bausch & Lomb from Warburg Pincus for $8.7 billion in a move to dominate the market for specialty contact lenses and related products.[37][38][39]

In January 2014, Valeant acquired Solta Medical for approximately $250 million.[40] In May 2014, Nestle acquired the commercial rights to some of Valeant's products for $1.4 billion.[41] In July 2014, Valeant acquired PreCision Dermatology Inc for $475 million.[42][43]

On April 1, 2015, Valeant completed the purchase of gastrointestinal treatment drug developer Salix Pharmaceuticals for $14.5 billion after outbidding Endo Pharmaceuticals.[44][45][46] On the final day of trading, Salix shares traded for $172.81, giving a market capitalisation of $10.9 billion. After the acquisition, Valeant raised the price of the diabetes pill Glumetza drastically.[47][48] In July 2015, the company announced it would acquire Mercury (Cayman) Holdings, the holding company of Amoun Pharmaceutical, one of Egypt's largest drugmakers, for $800 million.[49][50] In August 2015, Valeant said it would purchase Sprout Pharmaceuticals Inc for $1 billion, a day after Sprout received approval to market the women's libido drug Addyi.[51][52][53] In September 2015, Valeant licensed psoriasis drug Brodalumab from AstraZeneca for up to $445 million.[54][55] In September 2015, the company announced its intention to acquire eye surgery product manufacturer Synergetics USA, for $192 million in order to strengthen the company's Bausch & Lomb division.[56][57] In October 2015, the company's Bausch & Lomb division acquired Doctor's Allergy Formula for an undisclosed sum.[58]

On October 21, 2015, Citron Research founder Andrew Left, a short seller of Valeant shares, published claims that Valeant recorded false sales of products to specialty pharmacy Philidor Rx Services and its affiliates. Valeant controlled these specialty companies, allegedly resulting in improper revenue bookkeeping.[59] In addition, by controlling the pharmacy services offered by Philidor, Valeant allegedly steered Philidor's customers to expensive drugs sold by Valeant. One alleged practice entailed Valeant employees directly managing Philidor's business operations while posing as Philidor employees, and with all written communication under fictitious names.[60] Valeant responded that the allegations by Citron Research were "erroneous".[61] On October 30, 2015, Valeant said that it would cut ties with Philidor in response to allegations of aggressive billing practices.[62] Walgreens Boots Alliance Inc, owner of Walgreens, took over distribution for Valeant.[63]

An important part of the growth strategy for Valeant under Michael Pearson was the acquisition of medical and pharmaceutical companies and the subsequent price increases for their products.[64][65] This strategy attracted the attention of regulators in the United States,[65] particularly after the publication in The New York Times of an article on price gouging of specialty drugs.[66][67][68][69][70][47]

In September 2015, an influential group of politicians criticized Valeant on its pricing strategies.[69] The company raised prices on all its brand name drugs 66% in 2015, five times more than its closest industry peer. The cost of Valeant flucytosine was 10,000% higher in the United States than in Europe.[70][71] In late September 2015, members of the United States House Committee on Oversight and Government Reform urged the Committee to subpoena Valeant for their documents regarding the sharp increases in the price of "two heart medications it had just bought the rights to sell: Nitropress and Isuprel. Valeant had raised the price of Nitropress by 212% and Isuprel by 525%".[68][48]

By October 2015, Valeant had received subpoenas from the U.S. Attorney's Office for the District of Massachusetts and the United States Attorney for the Southern District of New York in regards to an investigation on Valeant's "drug pricing, distribution and patient assistance program."[72] The House Oversight Committee also requested documents from Valeant amid public concern around drug prices.[73][74]

In October 2015, the Federal Trade Commission began an investigation into Valeant's increasing control of the production of rigid gas permeable contact lenses. Valeant's acquisition of Bausch & Lomb in 2013, and Paragon Vision Services in 2015, is alleged to have given the company control of over 80% of the production pipeline for hard contact lenses. A series of unilateral price increases beginning in Fall 2015 spurred the FTC's investigation.[75] On November 15, 2016, Valeant agreed to divest itself of Paragon Holdings and Pelican Products to settle charges that its May 2015 acquisition of Paragon reduced competition for the sale of FDA-approved "buttons", the polymer discs used to make gas permeable contact lenses.[76][77]

In their 2015 annual report filed on April 29, 2016, Valeant said that it was the "subject of investigations" by the Securities and Exchange Commission, the U.S. Attorney's Offices in Massachusetts and New York, the state of Texas, the North Carolina Department of Justice, the Senate's Special Committee on Aging, and the House's Committee on Oversight and Reform, and had received document requests from the Autorite de Marches Financiers in Canada and the New Jersey State Bureau of Securities."[78]

In January 2016, presidential candidate Hillary Clinton said she would be "going after" Valeant for its price hikes, causing its stock price to fall 9 percent on the New York Stock Exchange.[79][80]

On April 27, 2016, Bill Ackman, J. Michael Pearson, and Howard Schiller were forced to appear before the United States Senate Special Committee on Aging to answer to concerns about the repercussions for patients and the health care system faced with Valeant's business model.[81]

By April 2016, the market value of hedge fund holdings in Valeant had fallen by $7.3 billion.[82] Hedge fund herding[83] continued to incite hedge fund portfolio managers to continue to buy Valeant shares.[82] From 2015 to 2017, Valeant shares plummeted more than 90 percent. This was later featured in episode 3 of the first season of the Netflix documentary Dirty Money.[84][82] In 2017, Ackman's Pershing Square fund, which held a major stake in the company, sold out for a reported loss of $2.8 billion.[85][86]

2016–2022: Valeant under Joseph Papa

[edit]

On April 25, 2016, Valeant named Perrigo chief executive Joseph Papa as a permanent replacement for Pearson, and entrusted him with turning around the company.[87] Papa set on a path of strategic sales, debt reduction, and organic growth.[88]

By January 2017, the company had sold its skincare brands to L'Oréal for $1.3 billion[89] and its Dendreon biotech unit to Sanpower for $819.9 million.[90] In June, the company sold iNova Pharmaceuticals for $910 million.[91] In July, the company also divested Obagi Medical Products for $190 million.[92] In November, it announced it would sell Sprout Pharmaceuticals back to its original owners, two years after acquiring the business for $1 billion.[93][94]

Under Papa's leadership, by early 2018, the company had become profitable again and had lowered its debt by $6.5 billion.[95] The company had divested itself of 13 non-core businesses, reducing its debt to $25 billion, and had settled or dismissed 70 pending lawsuits, including the Allergan insider trading case.[96] On January 8, 2018, the company announced that its Bausch + Lomb unit had received a CE Mark indicating conformity with health, safety, and environmental protection standards from the European Commission for the distribution of its Stellaris product in Europe.[97]

In July of 2018, Valeant rebranded to Bausch Health Companies, Inc.[98]

On December 16, 2019, the company settled a shareholder class action lawsuit under Section 11 of the U.S. Securities Act of 1933, alleging the company misled investors about its business operations and financial performance, for approximately $1.21 billion.[99][100] The company denied allegations of all wrongdoing as part of the settlement.[101][102]

On July 31, 2020, the SEC announced that Bausch Health had agreed to pay a $45 million penalty to settle charges of improper revenue recognition and misleading disclosures in SEC filings and earnings presentations. It also announced that Pearson would pay $250,000 in civil penalties to the SEC, as well as $450,000 to reimburse Valeant. Howard Schiller and Tanya Carro, two other executives who settled, paid the SEC $100,000 and $75,000, respectively.[103]

Recent developments

[edit]

In May 2022, Papa was replaced by Thomas J. Appio as the company's chief executive officer. John Paulson replaced Papa as chairman of Bausch Health after being on its board of directors from June 2017 to May 2022.[104]

In May 2023, Judge Richard G. Andrews upheld the court's original ruling, which blocks the FDA from approving Norwich Pharmaceuticals' 550 mg rifaximin generic until October 2029. Judge Andrews' decision bolsters his previous ruling that Norwich's abbreviated new drug application for rifaximin infringed on Bausch Health's Xifaxan patents for the reduction in risk of hepatic encephalopathy recurrence.[105]

In June 2023, the company's oral health business OraPharma partnered with Alex Rodriguez to launch its "Cover Your Bases" gum disease awareness campaign.[106]

Bausch Health Companies (Salix Pharmaceuticals) is supporting an investigator-initiated Phase 2 study of Relistor. The drug is intended for patients with resectable squamous cell carcinoma of the head and neck.[107]

As part of its fourth-quarter and full-year 2024 results, Bausch Health provided the following updates on its research and development activities:[108]

CABTREO®, a triple-combination therapy for the treatment of acne vulgaris, was launched in Canada in October 2024.

The RED-C clinical trial program, which is evaluating the prevention and delay of the first episode of overt hepatic encephalopathy, continues to progress. Both global Phase 3 studies are in the treatment phase and remain on track to deliver top-line Phase 3 results by early 2026.

Amiselimod, an S1P modulator and once-daily oral therapy for moderate to severe ulcerative colitis, advanced toward Phase 3 development. Draft protocols for the Phase 3 trial were submitted, and by the end of 2024, the company completed planned meetings with major regulatory agencies, including the FDA, EMA (EU), and PMDA (Japan). Regulatory feedback is currently under review.

Thermage® FLX, a radio-frequency technology designed to tighten skin and improve surface smoothness and texture, was submitted for regulatory approval in Canada during the fourth quarter of 2024. It was approved for the Canadian market in April 2025.[109]

Clear + Brilliant® Touch, a fractionated laser device for skin rejuvenation, received regulatory approvals in 2024 for several international markets, including Australia, New Zealand, the Philippines, Thailand, Taiwan, Malaysia, and Singapore. The product was also submitted for approval in Canada during the fourth quarter of 2024 and is currently awaiting a regulatory decision in Europe.

Acquisitions

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Bausch Health

View on Grokipedia
from Grokipedia

Bausch Health Companies Inc. is a Canadian-domiciled, U.S.-focused multinational holding company that develops, manufactures, and markets branded pharmaceuticals, generic drugs, over-the-counter products, and medical devices, primarily in the therapeutic areas of eye health, gastroenterology, dermatology, neurology, and oncology. Headquartered in Laval, Quebec, the company operates globally with a portfolio including the Bausch + Lomb eye care brand and drugs like Xifaxan for gastrointestinal disorders. Originally incorporated as Valeant Pharmaceuticals International in 1994, it pursued an aggressive acquisition strategy in the 2010s under CEO J. Michael Pearson, emphasizing low R&D spending, serial buyouts, and partnerships with specialty pharmacies to boost sales, which drove rapid revenue growth but also substantial debt accumulation exceeding $30 billion at its peak. This model faced intense scrutiny after revelations of improper revenue recognition practices involving the Philidor Rx Services pharmacy chain, leading to a 2015 stock plunge of over 90%, executive ousters, congressional hearings, and a $45 million SEC settlement in 2020 for accounting violations. The firm rebranded to Bausch Health in 2018 to shed its tarnished reputation, spun off Bausch + Lomb in 2022 for separate public trading, and has since focused on debt reduction and core product defense amid ongoing patent litigations and financial pressures.

History

Founding and early operations under ICN Pharmaceuticals (1959–2002)

Milan Panić, a Yugoslav immigrant who defected to the United States in the mid-1950s, founded ICN Pharmaceuticals in 1959 in a garage in Pasadena, California, initially with limited capital. The company, originally named International Chemical & Nuclear Corporation, began by commercializing deoxyribonucleic acid (DNA), marking an early focus on nucleic acid research and biochemical products. This foundational work laid the groundwork for subsequent developments in antiviral therapies. In its initial years, ICN expanded into , leveraging Panić's expertise in chemistry and to develop products like the ribavirin, marketed as Virazole for respiratory syncytial virus (RSV) treatment after FDA approval in 1986. The firm went public and grew through international operations, establishing manufacturing and research facilities in and , while achieving revenues exceeding $600 million by the late . However, growth was punctuated by regulatory challenges, including FDA rejections for broader ribavirin indications and scrutiny over data. Under Panić's leadership as CEO, ICN pursued acquisitions and diversified into generics and specialty pharmaceuticals, but faced investor discontent in the early amid stock underperformance and concerns. In June 2002, following a proxy battle led by major shareholders, Panić resigned from his positions as chairman and CEO, ending his direct operational control after over four decades. This transition marked the close of ICN's formative era, setting the stage for its rebranding to Valeant Pharmaceuticals in 2003.

Rebranding to Valeant and initial expansion (2002–2010)

In February 2002, the board of directors of ICN Pharmaceuticals ousted founder Milan Panić as chairman and CEO amid governance concerns and strategic disagreements. This leadership transition marked the end of Panić's long tenure, during which he had built ICN into a multinational pharmaceutical firm but faced criticism for erratic management and legal battles. Following Panić's removal, ICN underwent a to Valeant Pharmaceuticals International on , 2003, aiming to distance the company from past controversies and refocus on a streamlined portfolio of branded and specialty pharmaceuticals. The new name, derived from Latin roots meaning "to be strong" and "healthy," symbolized a shift toward international expansion and operational efficiency, with headquarters remaining in . Under interim and subsequent leadership, including figures like William Dow as acting CEO initially, Valeant prioritized divesting non-core assets and concentrating on , , and infectious disease segments. The post-rebranding period was marked by financial challenges, with Valeant reporting net losses for five consecutive years from through 2007, attributed to costs, setbacks, and a narrow product focus. growth was modest, driven by legacy ICN products like ribavirin for hepatitis C, but the company struggled with high debt from prior expansions and limited R&D investment. By 2006, Valeant secured U.S. FDA approval for Cesamet (nabilone), an for chemotherapy-induced , bolstering its supportive care portfolio. Efforts to expand geographically included bolstering presence in and through partnerships, though profitability remained elusive until late in the decade. Toward the end of the period, Valeant initiated targeted acquisitions to build scale and diversify. In January 2009, it acquired Dow Pharmaceutical Sciences for $285 million, gaining topical products like AcneFree and expanding manufacturing capabilities. The deal also included a Mexican generics firm, enhancing Latin American operations. In May 2010, Valeant purchased Aton Pharma for approximately $26.6 million, adding Nascobal ( ) for to its specialty lineup. These moves signaled a pivot toward inorganic growth. The decade culminated in September 2010 with Biovail Corporation's acquisition of Valeant in a $3.3 billion deal, merging the two firms under the Valeant name and relocating headquarters to , setting the stage for accelerated expansion.

Acquisition-driven growth under Pearson (2010–2016)

Under J. Michael Pearson's leadership, Valeant Pharmaceuticals pursued a strategy of serial acquisitions to rapidly expand its portfolio of established drugs, prioritizing external growth over internal . Pearson, appointed CEO in 2008 and steering the company through its 2010 reverse merger with , emphasized acquiring firms with mature products that could be integrated into Valeant's operations while implementing cost synergies such as workforce reductions and facility consolidations. This approach, rooted in Pearson's McKinsey background in pharmaceutical deal-making, aimed to generate through pricing optimization and efficient distribution channels, including partnerships with specialty pharmacies, rather than investing heavily in new . By 2014, Valeant had completed over 100 tuck-in acquisitions since 2010, transforming it from a mid-sized player with approximately $700 million in annual into a multinational entity with diversified therapeutic areas including , , and . Key acquisitions during this period significantly bolstered Valeant's scale and market position. In May 2010, Valeant acquired Aton Pharmaceuticals for $318 million, gaining rights to drugs like Xifaxan. This was followed by the $2.6 billion purchase of Medicis Pharmaceutical in 2012, which added dermatological treatments such as Solodyn and facial fillers competing with Botox. The landmark $8.7 billion acquisition of in August 2013 provided a strong foothold in eye care products, including contact lenses and surgical devices, and represented Valeant's largest deal to date. In 2015, the company completed its biggest transaction by acquiring Salix Pharmaceuticals for $10.96 billion in cash plus assumed debt totaling approximately $15.8 billion, incorporating gastrointestinal therapies like Xifaxan that became central to revenue streams.
AcquisitionDateValueKey Assets
Aton PharmaceuticalsMay 2010$318 million products (e.g., Feraheme)
Medicis Pharmaceutical2012$2.6 billion drugs and fillers
Bausch + LombAugust 2013$8.7 billionEye care (lenses, surgery)
Salix Pharmaceuticals2015$10.96 billion (cash) + debtGI therapies (e.g., Xifaxan)
This acquisition spree propelled revenue growth from $1.75 billion post-2010 merger to $8.2 billion in and $10.4 billion in , with stock returns exceeding 900% from mid-2010 levels amid investor enthusiasm for the model's high returns on capital. However, the relied on leveraging substantial —reaching over $30 billion by —and post-acquisition price increases on legacy drugs, which averaged hundreds of percent in some cases, to realize synergies. While delivering short-term expansion, these tactics drew early regulatory and media scrutiny over access and impacts, foreshadowing challenges by late .

Restructuring and shift to Bausch Health under Papa (2016–2022)

In May 2016, Joseph C. Papa was appointed chief executive officer and chairman of the board of Valeant Pharmaceuticals International, Inc., succeeding amid a severe characterized by over $30 billion in debt, regulatory investigations, and sharp declines in stock value. Papa's initial strategy emphasized divesting non-core assets to generate cash for debt reduction, stabilizing the sales force, and reallocating resources toward , reversing prior emphases on acquisitions and cost-cutting at the expense of innovation. Key divestitures included the sale of iNova Pharmaceuticals to an affiliate of Holdings Limited for approximately $930 million in June 2017, and the sale of Obagi Medical Products, Inc., for $190 million in November 2017, with proceeds directed toward retiring senior secured debt. These transactions contributed to a broader effort that reduced net debt by more than $6 billion from a peak of $32 billion through asset sales, refinancing, and operational cash flows by early 2018. In January 2017, Papa outlined a target to pay down an additional $5 billion in debt over the subsequent 18 months, prioritizing senior secured obligations to improve and credit metrics. R&D spending increased, with plans for a roughly 10% annual boost starting around 2019, focusing on core areas such as , , and . On May 8, 2018, the company announced its rebranding to Bausch Health Companies Inc., effective July 2018, to honor the heritage of the eye care business while distancing itself from Valeant's reputational damage associated with controversies and distribution practices. Trading under the ticker "BHC" began on , 2018, coinciding with updated and a website relaunch. Debt reduction continued post-rebranding, with over $1 billion allocated in 2019 toward paydowns or selective acquisitions, and further redemptions such as $275 million in senior secured term loans in December 2020 using operational cash. From 2020 onward, restructuring accelerated toward segmenting operations, including plans to spin off the aesthetics device business Solta Medical in 2021 to support additional , and culminating in the and separation of Corporation in May 2022, which generated proceeds to reduce Bausch Health's leverage. Papa resigned as chairman and CEO of Bausch Health in June 2022 to lead exclusively, having overseen a net debt reduction of approximately $7 billion since 2016, though the company retained substantial obligations exceeding $20 billion.

Stabilization and recent strategic moves (2022–present)

In May 2022, Bausch Health appointed Thomas J. Appio as , succeeding Joseph W. Papa, amid efforts to refocus the company on core operations following years of high leverage and . Appio's leadership emphasized stabilizing cash-generating segments including , , generics, and (primarily via Salix Pharmaceuticals), while advancing the separation of the eye health business. A pivotal move occurred on May 10, 2022, with the closing of 's , generating approximately $630 million in gross proceeds for Bausch Health and enabling $2.5 billion in new financing at Bausch + Lomb, which facilitated repayment of intercompany obligations. This transaction contributed to a $3.2 billion reduction in Bausch Health's (excluding Bausch + Lomb) by the end of 2022, alleviating immediate liquidity pressures and allowing sharper focus on non-eye health portfolios. Concurrently, the company pursued a distressed exchange in August 2022, targeting approximately $11.8 billion in unsecured notes to extend maturities and improve flexibility, though rated 'C' by Fitch due to recovery risks. From 2023 onward, Bausch Health reported progressive growth, with full-year 2023 revenues reaching $8.76 billion, an 8% increase from $8.12 billion in 2022, driven by 6% in key areas like Salix (up 8%). Adjusted EBITDA rose to $2.36 billion, supporting $708 million in adjusted , while strategic litigation wins, such as a favorable motion in Xifaxan disputes, bolstered gastrointestinal product defenses and revenue outlook. levels fluctuated, declining to $20.76 billion by end-2022 before rising to $22.38 billion in 2023 and $21.61 billion in 2024, reflecting ongoing paydowns offset by refinancings. In 2025, Bausch Health accelerated deleveraging with a July announcement to reduce debt by approximately $900 million using cash on hand, including $602 million in senior notes redemption and $300 million repayment under its receivables facility. This followed a $7.4 billion refinancing in April to address near-term maturities and end a prolonged Bausch + Lomb spin-off effort, though operational risks persisted amid $14.65 billion net debt. Q2 2025 revenues hit $2.53 billion, up 5% year-over-year (4% organic), prompting raised full-year guidance to $5.05–$5.15 billion, with emphasis on pipeline expansion and board enhancements via additions like Michael Goettler and Sandra Leung for governance and expertise. Additional moves included withdrawing high-cost drugs like Xifaxan from 340B and Medicaid rebate programs in September 2025 to optimize pricing and margins. These initiatives signal a shift toward sustainable cash flow generation, though total debt remains elevated relative to equity.

Business Strategy

Serial acquisition model and cost efficiencies

Bausch Health, formerly Valeant Pharmaceuticals, adopted a serial acquisition strategy emphasizing frequent, debt-financed purchases of companies with established product portfolios in specialty areas such as , , and , rather than heavy investment in internal . This approach, accelerated under CEO Michael Pearson from 2010 onward, involved over 100 acquisitions between 2008 and 2015, targeting mature assets with limited patent cliffs to minimize innovation risks and maximize near-term flows. Post-acquisition integration focused on rapid cost efficiencies to enhance margins, primarily through reductions in selling, general, and administrative () expenses, (R&D) spending, and headcount. For instance, the 2013 acquisition of for $8.7 billion was projected to yield at least $800 million in annual cost savings by the end of 2014, derived from manufacturing optimizations, consolidations, and elimination of redundant R&D programs, alongside workforce reductions affecting approximately 20% of the combined staff. Similarly, the 2015 purchase of Salix Pharmaceuticals anticipated over $500 million in yearly synergies from SG&A cuts and operational streamlining. These efficiencies were achieved via centralized , facility rationalizations, and a deliberate de-emphasis on R&D, which Valeant maintained at under 3% of revenues compared to industry averages exceeding 15%, redirecting savings toward debt service and shareholder returns. The 2010 merger with , for example, delivered $175 million in annual cost reductions through administrative overlaps and geographic consolidations. While this model drove revenue growth from $817 million in 2008 to over $10 billion by 2015, it relied on leveraging low-interest debt, amplifying risks during rising rates. In the post-2016 restructuring under CEO Joseph Papa, Bausch Health moderated the serial pace but retained elements of the model, pursuing targeted bolt-on deals like the 2019 acquisition of Pharmaceuticals' assets for $195 million to bolster offerings with minimal integration costs. Recent moves, such as the 2025 DURECT Corporation deal valued at up to $413 million, continue to emphasize synergy capture through portfolio alignment rather than expansive R&D expansion. This evolution reflects a tempered focus on sustainable efficiencies amid ongoing debt management.

Approach to R&D, pricing, and distribution

Bausch Health, formerly Valeant Pharmaceuticals, has historically prioritized acquisitions over substantial internal (R&D) investment, viewing much traditional pharmaceutical R&D as inefficient and low-return. Under CEO Michael Pearson from 2008 to 2016, the company reduced R&D spending from approximately 11% of revenue in 2007 to 3% by 2013, reallocating resources to purchasing late-stage assets from other firms rather than funding early-stage discovery. This approach contrasted with industry norms of 15-20% R&D allocation, as Valeant executives argued that external acquisitions provided higher returns with lower risk. Following the 2015-2016 crisis involving debt overload and pricing scrutiny, Bausch Health shifted under CEO Joseph Papa (2016-2022) and successors toward modest R&D increases, emphasizing targeted pipeline advancement in core areas like and . R&D expenses rose from $465 million in 2021 to $604 million in 2023 and $616 million in 2024, representing about 7% of in recent years amid total revenues of $8.76 billion in 2023. The company has intensified focus on specific programs, such as advancing amiselimod into Phase 3 trials for , while pursuing business development deals to supplement internal efforts. This evolution reflects a balance between cost discipline and innovation to support products like Xifaxan, though R&D remains below peers, prioritizing efficiency over broad exploration. On pricing, Bausch Health has employed aggressive increases on acquired drugs to generate for debt servicing and operations, a strategy rooted in the Valeant model of hiking prices post-purchase without proportional R&D offsets. This drew criticism during the for exacerbating access issues, as seen in sharp markups on legacy generics and treatments. More recently, the company has restricted participation in discount programs to preserve net pricing, including exiting the Drug Rebate Program and in 2025, and imposing conditions on 340B contract pharmacy deliveries since 2022. These moves, affecting high-cost therapies like those for , aim to centralize control and reduce rebate obligations, though they have faced legal challenges from providers alleging unlawful restrictions. Bausch Health complements this with patient assistance programs offering free medication to eligible uninsured patients, mitigating some access barriers without broad price concessions. Distribution relies on a hybrid model leveraging global and partnerships, with 45 sites worldwide handling production and as of recent reports. Products reach markets primarily through pharmaceutical wholesalers (about 45% of channels), retail pharmacies (30%), and hospitals/institutions, supplemented by direct distribution for select national drug codes (NDCs) under alternative plans to streamline 340B compliance. Subsidiaries like have experimented with elements for eye care, building proprietary databases to track usage, but core pharmaceuticals emphasize established wholesale and institutional pathways for efficiency. This structure supports geographic focus on high-growth regions while minimizing overhead, aligning with the company's emphasis on operational rigor over expansive networks.

Debt management and capital allocation

Bausch Health Companies Inc., formerly Valeant Pharmaceuticals, accumulated substantial debt through an aggressive serial acquisition strategy in the early , peaking at approximately $30 billion by amid a triggered by revelations of unsustainable leverage, pricing controversies, and reliance on specialty pharmacy channels. This led to credit rating downgrades, stock price collapse, and operational distress, prompting a strategic pivot under new CEO Joseph Papa in toward deleveraging as a core priority. The company rebranded to Bausch Health in 2018 and committed to reducing debt through divestitures, generation, and , targeting $5 billion in paydowns within 18 months from such proceeds by late 2017, though full realization extended amid market challenges. Post-crisis restructuring included distressed debt exchanges, such as the 2022 offer of up to $2.5 billion in first-lien secured notes and $500 million in second-lien notes to extend maturities and avert defaults. By 2020, incremental reductions like $275 million in term loan paydowns demonstrated progress using operational cash, though total debt remained elevated. The 2022 spin-off of aimed to streamline operations and unlock value for debt reduction, but faced litigation from investors seeking to void portions to satisfy fraud claims, highlighting tensions between and creditor priorities. As of March 31, 2025, total stood at levels implying a exceeding 14,000%, underscoring persistent leverage risks despite net reduction of nearly $1 billion in 2024 alone through cash flow and selective refinancings. In 2025, Bausch Health accelerated deleveraging with targeted actions, including a July 28 announcement to repay approximately $900 million using cash on hand—comprising $602 million in 9% senior notes due 2027 and full payoff of a $300 million receivables facility—aimed at easing near-term maturities and high-interest obligations. An April refinancing involved issuing $7.9 billion in new instruments to retire 2025-2026 payments, extending durations while maintaining focus on capital structure optimization. Further, Q2 2025 earnings highlighted repayments of 2026-maturing debt and reductions in the receivables facility to curb interest expenses, with expectations of continued intermediate-term deleveraging tied to product cash flows like XIFAXAN. Capital allocation under Bausch Health emphasizes debt reduction as the overriding principle, directing primarily to principal repayments and refinancings over dividends, share repurchases, or expansive acquisitions, a departure from the prior Valeant model's growth-at-all-costs approach. This disciplined framework, informed by post-2016 lessons on over-leverage, limits to essential R&D and , with divestiture proceeds earmarked for repair rather than reinvestment. Recent progress has enabled tentative shareholder-oriented moves, such as post-Icahn shifts signaling potential returns once milestones are met, though high debt levels constrain broader distributions. Overall, this strategy reflects causal prioritization of to mitigate default risks, with 2025 guidance integrating debt paydown alongside modest revenue growth targets of $5.05–5.15 billion.

Major Acquisitions

Pre-2010 foundational deals

Valeant Pharmaceuticals International, rebranded from ICN Pharmaceuticals in 2003, initiated its acquisition strategy with targeted purchases to expand into neurology and dermatology portfolios prior to the more aggressive expansion phase beginning in 2010. In February 2005, Valeant acquired Xcel Pharmaceuticals, Inc., a San Diego-based firm, for $280 million in cash plus assumption of $44 million in debt, gaining access to neurology products including Zelapar for Parkinson's disease treatment and retigabine, an epilepsy drug candidate in development. This deal strengthened Valeant's neurological pipeline and marked an early step in bolstering its specialty therapeutics beyond generics. By 2008, under new CEO , Valeant accelerated dermatology-focused deals. In September 2008, it purchased Coria Laboratories for $95 million, adding topical treatments for and to its offerings. Later that year, in November, Valeant acquired DermaTech, an Australian dermatology firm, for $12.6 million, further enhancing its international skin care assets. These transactions aligned with Valeant's emerging model of acquiring established products rather than heavy internal R&D investment. In 2009, Valeant continued this approach with larger dermatology plays. The company acquired Dow Pharmaceutical Sciences in for $285 million, securing rights to Locoid, a topical for inflammatory skin conditions, and advancing its U.S. presence. Also in , Valeant bought Tecnofarma, a generic drugmaker, to expand its Latin American generics footprint, though specific value details were not disclosed. In July 2009, it further targeted generics via Tecnofarma integration, and by December, its Canadian subsidiary acquired Laboratoire Dr. Renaud for C$23 million, adding cosmetic lines. These pre-2010 deals, totaling over $670 million in disclosed values, laid the groundwork for Valeant's serial acquisition strategy by prioritizing bolt-on purchases of marketed products in high-margin therapeutic areas, setting the stage for the Biovail reverse merger in September 2010 that combined revenues exceeding $1.75 billion.

Peak acquisition phase (2010–2016)

During this period, Valeant Pharmaceuticals International, Inc. executed an aggressive serial acquisition strategy under CEO , acquiring companies primarily in , , and gastrointestinal therapeutics to rapidly expand its portfolio of mature branded products. The approach emphasized debt-financed purchases of firms with established revenues but limited R&D pipelines, followed by cost reductions, efficiencies, and price increases rather than internal innovation. Between 2011 and 2015, Valeant spent approximately $32 billion on acquisitions, transforming annual revenue from about $1.75 billion post-2010 merger to over $10 billion by 2015, while accumulating around $30 billion in debt. Key deals included the February 2011 acquisition of PharmaSwiss S.A., a Switzerland-based generics firm, for €350 million (approximately $481 million), which bolstered Valeant's European presence in and cardiovascular drugs. In July 2011, Valeant purchased Ortho Dermatologics from for $345 million, adding topical dermatology treatments like Elidel and Lidoderm to its portfolio. That same year, it acquired AB Sanitas for about $500 million, expanding in the , and Sanofi's Dermik unit, further strengthening dermatological offerings. In December 2012, Valeant completed its $2.6 billion purchase of Medicis Pharmaceutical Corp., gaining anti-aging products such as and Perlane fillers, positioning it as a competitor to in . The August 2013 acquisition of for $8.7 billion marked Valeant's largest deal, integrating a leading eye health company with contact lenses, surgical equipment, and pharmaceuticals like Lotemax, and creating a dedicated division. In January 2014, it acquired Solta Medical for approximately $250 million, adding aesthetic devices such as Fraxel lasers for skin resurfacing. The phase culminated in the April 2015 $11 billion acquisition of Salix Pharmaceuticals, which provided blockbuster gastrointestinal drugs including Xifaxan and Apriso, contributing over 20% to Valeant's revenue post-integration. Smaller transactions, such as the 2012 purchase of Russia's Natur Produkt for $180 million (cough and cold remedies), supported geographic diversification. This acquisition spree, while driving short-term growth, drew scrutiny for opaque accounting practices and reliance on specialty pharmacies like Philidor, which inflated sales figures and contributed to a 2015 stock plunge amid investigations.
YearTargetValueFocus Area
2011PharmaSwiss S.A.$481 millionGenerics (CNS, CV)
2011Ortho Dermatologics$345 millionDermatology
2011AB Sanitas~$500 millionRegional expansion
2012Medicis Pharmaceutical$2.6 billionAesthetics/dermatology
2013Bausch & Lomb$8.7 billionOphthalmology
2014Solta Medical$250 millionAesthetic devices
2015Salix Pharmaceuticals$11 billionGastroenterology

Post-crisis and recent acquisitions including DURECT (2016–present)

Following the 2015–2016 crisis involving sharp stock declines, regulatory scrutiny, and high debt levels exceeding $30 billion, Bausch Health adopted a more conservative approach to , emphasizing debt repayment, asset divestitures, and internal efficiencies over expansive deal-making. This shift reduced the volume of transactions compared to the pre-crisis era, with post-2016 activity limited primarily to smaller, targeted bolt-on deals that complemented core franchises in eye health, , and without significantly increasing leverage. For instance, the company pursued selective opportunities in medical devices and therapeutics, such as enhancements to its portfolio, while avoiding the leveraged buyouts that characterized earlier growth. By the early 2020s, as debt levels stabilized through refinancings and operational improvements, Bausch Health began exploring strategic additions to emerging areas like and , aligning with a renewed focus on pipeline expansion amid patent cliffs for legacy products. This included modest investments in adjuncts via its subsidiary, though parent-level deals remained measured. A pivotal recent acquisition occurred in 2025 with DURECT Corporation, a developer of biotherapeutics for chronic conditions including and . Announced on July 29, 2025, and completed on September 11, 2025, Bausch Health purchased all outstanding shares of DURECT for $1.75 per share in cash, equating to an upfront payment of approximately $63 million plus contingent payments potentially reaching $350 million, for a total enterprise value up to $413 million. The deal granted Bausch Health full rights to DURECT's lead candidate, larsucosterol (LARS-1703), an oral investigational therapy in Phase 3 trials for severe (SAH), which received FDA Designation in 2024 due to promising Phase 2b data showing reduced mortality risk. This acquisition expanded Bausch Health's nascent portfolio, targeting a high-unmet-need indication where SAH mortality exceeds 30% within 28 days, and positioned the company to leverage DURECT's proprietary platform for future applications in metabolic and inflammatory disorders. Following the merger, DURECT became a wholly owned subsidiary, with its shares delisted from . Company executives described the move as strengthening commitment to innovative solutions, integrating DURECT's assets into Bausch Health's broader gastrointestinal and emerging therapies strategy.

Product Portfolio

Eye health and Bausch + Lomb integrations

Bausch Health acquired in May 2013 for $8.7 billion, integrating its pre-existing ophthalmology portfolio into the division to establish a unified global eye health platform spanning vision care, surgical equipment, and pharmaceutical therapies. This merger combined 's established contact lens and surgical expertise with Valeant's (now Bausch Health's) targeted ophthalmic drugs, enabling cross-segment synergies in research, manufacturing, and distribution. The integrated eye health operations under focus on three primary categories: vision care, including daily disposable silicone hydrogel contact lenses like Infuse; surgical systems for removal and procedures; and pharmaceuticals addressing , dry eye disease, and other ocular conditions. In September 2023, enhanced its dry eye franchise by acquiring XIIDRA ( ophthalmic solution) and related assets from for up to $2.5 billion, including $1.75 billion upfront, which propelled the portfolio to approximately $1 billion in trailing 12-month revenue by mid-2025. Despite the May 2022 of , which raised funds for Bausch Health's debt reduction, the parent company retains an 88% ownership stake as of February 2025, maintaining financial consolidation and strategic oversight of eye health activities. Full separation efforts, including explored sales to private buyers, have not advanced to completion, preserving operational integrations such as shared supply chains and R&D pipelines while allowing to operate with dedicated leadership. The segment contributed $4.79 billion in revenue for full-year , representing a core pillar of Bausch Health's diversified portfolio amid ongoing volatility in other areas.
SegmentKey Focus Areas2024 Revenue Contribution
Vision CareContact lenses (e.g., Infuse), solutions$2.74 billion
Surgical, retinal tools and systems~$216 million (Q2 benchmark)
Pharmaceuticals drugs, dry eye (e.g., XIIDRA)Dry eye: ~$1 billion (trailing 12 months to Q2 2025)

Dermatological and gastrointestinal therapies

Bausch Health maintains a dermatology portfolio targeting conditions including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, and nail fungus, marketed through its Ortho Dermatologics division. Key prescription products encompass Aldara (imiquimod 5% cream) for actinic keratosis and superficial basal cell carcinoma; Altreno (tretinoin 0.05% lotion) and Arazlo (tazarotene 0.045% lotion) for acne vulgaris; Duobrii (halobetasol propionate 0.01% and tazarotene 0.045% lotion) for plaque psoriasis; Jublia (efinaconazole 10% topical solution) for onychomycosis; and Qbrexza (glycopyrronium tosylate 3.75% cloth) for primary axillary hyperhidrosis. Over-the-counter offerings include AcneFree for acne management and Abreva for herpes labialis. The company's gastrointestinal therapies, largely under Salix Pharmaceuticals, address , , opioid-induced , and chronic idiopathic . Xifaxan (), a flagship product generating substantial revenue, is approved for reducing overt recurrence in adults and treating with diarrhea in adults. Relistor (methylnaltrexone bromide), available as subcutaneous injection and oral tablet, treats opioid-induced in adults with chronic non-cancer pain or advanced illness, including . Trulance (), a guanylate cyclase-C agonist, is indicated for chronic idiopathic and with in adults. Additional products like Apriso (mesalamine extended-release capsules) manage maintenance. These therapies emphasize gut-targeted antibiotics, laxatives, and secretagogues, with Xifaxan comprising a core revenue driver in the segment as of 2025.

Neurological, pain management, and emerging pipelines

Bausch Health maintains a portfolio of established pharmaceuticals targeting neurological conditions such as epilepsy, migraines, and depression, primarily through generics and branded generics in its Diversified Products segment. Key products include Mestinon (pyridostigmine bromide) tablets and extended-release formulations, indicated for the symptomatic treatment of myasthenia gravis, a neuromuscular disorder affecting voluntary muscle control. Migranal (dihydroergotamine mesylate) nasal spray is approved for the acute treatment of migraine attacks with or without aura in adults. For depression, the company offers Wellbutrin (bupropion hydrochloride) extended-release tablets and Aplenzin (bupropion hydrobromide) extended-release tablets, both used as antidepressants with mechanisms involving norepinephrine and dopamine reuptake inhibition. These neurology offerings generated revenue within the company's generics and other categories, though specific 2024 sales figures for individual neurological products were not itemized in public disclosures. In , Bausch Health's primary contribution is Relistor ( ), available as subcutaneous injection and oral tablets, indicated for -induced (OIC) in adults with chronic non-cancer who have inadequate response to laxatives. Relistor acts as a peripherally acting mu- , blocking opioid effects in the without diminishing central analgesia, thereby supporting continued control via opioids. Clinical data from phase 3 trials demonstrated response rates of approximately 48% for in non-cancer patients, with common adverse events including and . Marketed through subsidiary Salix Pharmaceuticals, Relistor addresses a complication affecting up to 40% of chronic users, though its has been tempered by high pricing and competition from generics like . Bausch Health's emerging pipelines as of September 2025 show limited advancement in neurological or therapeutics, with efforts predominantly allocated to , , and . No phase 2 or 3 candidates specific to , migraines, depression, or direct modulation were highlighted in recent updates, reflecting a strategic emphasis on core GI assets like extensions and amiselimod for . The 2025 acquisition of DURECT Corporation added larsucosterol, a phase 2b asset for alcohol-associated granted FDA designation, but this bolsters rather than or . Overall, innovation in these areas appears constrained, relying on lifecycle management of legacy products amid Bausch Health's post-crisis focus on debt reduction and operational efficiencies.

Controversies and Criticisms

Drug pricing strategies and market responses

Bausch Health, formerly Valeant Pharmaceuticals, employed a emphasizing acquisitions of established drugs followed by significant price increases to drive revenue growth, rather than substantial investment in . This approach involved targeting off-patent medications with limited generic competition, such as Xifaxan () for gastrointestinal conditions and Syprine (trientine) for , where list prices were raised by hundreds of percent in some cases. For instance, Valeant implemented a 500% price hike on Glumetza (metformin extended-release) in 2015, which contributed to undisclosed revenue dependencies from wholesalers. These strategies drew intense market and regulatory scrutiny, including U.S. hearings in April 2016 where then-CEO Michael Pearson expressed regret over the hikes, acknowledging they preempted generic entry but fueled public outrage. The Special on Aging's 2015 highlighted Valeant's "enormous price increases" on multiple drugs, prompting investigations into practices across the industry. Shareholder lawsuits and a sharp stock decline—over 90% from peak levels—followed, exacerbating Valeant's and leading to its rebranding as Bausch Health in 2018. Post-rebranding, Bausch continued selective price adjustments, particularly in its Salix unit for drugs like Xifaxan, contributing to quarterly revenue gains as of 2019. Tactics included larger package sizes with higher per-milligram pricing, as seen in adjustments to established products. To maintain pricing power, the company engaged in alleged pay-for-delay agreements, such as a 2012 settlement with generic makers for Glumetza, resulting in a $300 million antitrust payout in 2021. Similar accusations persist with Xifaxan, where Bausch and Teva faced claims in 2025 of conspiring to delay generics, potentially preserving high prices for the $1.9 billion annual seller. Market responses included ongoing legal and regulatory actions, such as a 2020 SEC settlement of $45 million for Valeant-era revenue misstatements tied to pricing impacts and a 2022 DOJ probe into tactics for four medications. In 2025, Bausch withdrew much of its catalog, including high-cost Xifaxan, from the 340B discount program, citing contract pharmacy obligations, which hospitals criticized as limiting access amid elevated list prices. These moves reflect persistent tensions, with investor sentiment incorporating risks into valuations, though recent stock surges have occurred amid deleveraging efforts.

Philidor pharmacy distribution issues

In 2014, Valeant Pharmaceuticals International, Inc. (rebranded as Bausch Health Companies Inc. in 2018) formed a distribution partnership with Philidor Rx Services, a mail-order it helped establish and fund through an exclusive supply agreement for select products, including high-priced dermatological and gastrointestinal drugs like Xifaxan. This arrangement enabled Valeant to channel a significant portion of —reaching approximately 8% of quarterly U.S. by mid-2015—directly through Philidor, bypassing traditional wholesalers and leveraging the 's copay assistance programs to promote Valeant-branded generics over cheaper alternatives. The model relied on Philidor's practices of automatic patient enrollment in refill programs and prescription modifications to favor Valeant drugs, which critics later argued inflated demand artificially by shipping medications patients had not explicitly requested or needed. Allegations of misconduct surfaced prominently in October 2015 following a Citron Research report accusing Philidor of fraudulent tactics, such as using other pharmacies' National Provider Identifier (NPI) numbers to bill insurers and evade scrutiny, as well as engaging in "channel stuffing" by accepting excess inventory from Valeant to prematurely recognize revenue. These practices reportedly allowed Valeant to report sales upon shipment to Philidor rather than upon delivery to end patients, treating consignment-like transactions as final despite return risks exceeding 30% in some cases. Pharmacy benefit managers (PBMs) rapidly severed ties with Philidor amid these revelations, prompting Valeant to terminate the relationship on October 30, 2015, and Philidor to cease operations shortly thereafter. Valeant denied fraud but acknowledged "improper behavior" at Philidor had disturbed stakeholders. The U.S. Securities and Exchange Commission (SEC) investigated Valeant's Philidor disclosures starting in late 2015, finding that the company failed to reveal the interdependent relationship—including Valeant's financial backing and control over Philidor's operations—and omitted risks such as high return rates and dependency on the pharmacy for reported growth. SEC orders determined Valeant had improperly recognized about $58 million in revenue from Philidor transactions, necessitating restatements for quarters from September 2014 through June 2015. In July 2020, Bausch Health settled the charges without admitting or denying wrongdoing, agreeing to a $45 million civil penalty to resolve all SEC claims related to the matter. Related criminal proceedings highlighted kickback schemes: in May 2018, former Valeant senior director Gary Tanner and ex-Philidor executive were convicted of and kickbacks for schemes involving payments to a for inflated prescriptions of Valeant products, including Jublia, routed through Philidor. Civil litigation followed, with Valeant settling Racketeer Influenced and Corrupt Organizations Act (RICO) claims for $23 million in 2021 over allegations of secret manipulations to boost revenues. These issues contributed to broader scrutiny of Valeant's but were distinct from parallel probes into and other distribution channels.

Securities investigations and shareholder impacts

In the fourth quarter of 2015, the U.S. Securities and Exchange Commission (SEC) initiated an investigation into Valeant Pharmaceuticals International, Inc. (subsequently renamed Bausch Health Companies Inc.), focusing on the company's accounting practices related to its distribution partnership with Philidor Rx Services. The probe examined allegations of improper from Philidor-facilitated sales, failure to disclose the extent of Valeant's dependence on the for a significant portion of its —up to 7-10% in affected quarters—and deficiencies in internal accounting controls under Section 13(b)(2)(B) of the Securities Exchange Act of 1934. These issues stemmed from Valeant's practice of shipping products to Philidor ahead of verified patient demand, inflating reported across five quarters from Q3 to Q1 , while public disclosures portrayed Philidor as a standard specialty rather than a closely affiliated channel risking channel stuffing. The SEC investigation concluded on July 31, 2020, with Bausch Health agreeing to a $45 million to settle charges without admitting or denying wrongdoing, fully resolving all related claims against the company. Former CEO and other executives faced separate administrative proceedings, resulting in additional penalties totaling $45.425 million collectively, including disgorgement and prejudgment interest for misleading investor disclosures. Complementary probes by the U.S. Department of Justice (DOJ) into potential criminal aspects, such as kickbacks to Philidor, did not yield charges against the company but contributed to heightened regulatory scrutiny on Valeant's overall business model. The revelations and investigations triggered immediate shareholder impacts, with Valeant's stock price dropping sharply on , 2015—falling 10.4% from $163.83 to $146.74 per share following congressional inquiries into Philidor—amid broader concerns over practices and . Over the ensuing months, the shares declined more than 90% from their mid-2015 peak near $260, erasing approximately $80 billion in by early 2016 as investor confidence eroded due to restated financials and halted Philidor operations. This volatility prompted multiple lawsuits alleging through material misstatements; the primary U.S. action, covering purchases from February 2012 to November 2015, settled for $1.21 billion in 2020 after years of litigation, providing recovery to affected investors. A parallel Canadian resolved for C$94 million in August 2020. Longer-term effects included sustained pressure on Bausch Health's equity, with shares trading below $20 for much of the post-crisis period until partial recovery measures like asset spin-offs, though legacy overhang from the probes persisted in sentiment and reforms. A 2025 shareholder suit alleging concealment of ongoing regulatory risks was dismissed by a federal court, underscoring evolving judicial assessments of disclosure adequacy post-settlement. Bausch Health settled U.S. Securities and Exchange Commission (SEC) charges in July 2020 related to Valeant-era practices, including improper tied to the Philidor Rx Services distribution arrangement and misleading disclosures on pricing impacts, agreeing to a $45 million on negligence-based claims without admitting or . Former executives, including CEO and CFO Howard Schiller, paid personal penalties of $250,000 and $100,000 respectively, plus , while the company emphasized the resolution closed legacy investigations without intent-based findings. Separate criminal convictions were upheld in 2019 against two former Philidor executives for defrauding Bausch through fictitious sales, though no company-level criminal charges resulted from the U.S. Department of Justice probe into Philidor channel stuffing. Shareholder securities class actions stemming from stock declines amid the 2015-2016 revelations yielded major settlements without admissions of : $1.21 billion in the U.S. federal case covering misstatements on Philidor dependencies and , approved after five years of litigation. A parallel Canadian resolved for CAD $94 million. Pricing-related civil suits included a $23.125 million settlement in 2022 with third-party payors over alleged artificial of drugs like Xifaxan and Glumetza, and a $300 million antitrust resolution in 2021 for maintaining a monopoly on the diabetes drug through invalid patents and pay-for-delay deals. Racketeer Influenced and Corrupt Organizations Act (RICO) claims alleging a secret pharmacy network to block generics settled for $23 million in 2021. Company defenses framed the Philidor partnership as a legitimate distribution to bypass pharmacy benefit manager restrictions and expand access to high-margin products, with executives arguing it accelerated without violating standards until scrutiny revealed over-reliance and disclosure gaps. On , Bausch maintained that increases reflected the value of niche therapies like Xifaxan for rare conditions such as , where limited competition and high development costs—amid industry-wide R&D expenditures averaging $1-2 billion per approved drug—justified premiums to recoup investments, rejecting claims of gouging as disconnected from causal factors like patent-protected and clinical efficacy. Post-settlement statements highlighted remediation, changes, and a shift to sustainable growth, with no ongoing SEC enforcement as of 2020. These episodes occurred amid broader pharmaceutical industry dynamics where aggressive pricing and specialized distribution networks, including limited pharmacy partnerships, are prevalent to navigate opaque supply chains involving wholesalers, insurers, and rebate systems that can inflate list prices while net revenues remain pressured by negotiations. High launch prices for specialty drugs often exceed marginal production costs due to inelastic demand for treatments addressing unmet needs, balanced against high failure rates in R&D pipelines and finite exclusivity periods under patents, though critics note systemic markups enable shareholder returns; Bausch's tactics, while extreme, mirrored patterns seen in cases like EpiPen hikes by or opioid distribution by Insys, underscoring incentives for revenue maximization in a regulated yet competitive market where shows prices correlating more with than proportional R&D recovery.

Financial Performance

Historical revenue growth and volatility

Bausch Health, formerly known as Valeant Pharmaceuticals until its in 2018, achieved explosive growth between 2011 and 2015 through an aggressive strategy of serial acquisitions and limited internal R&D investment. Revenues rose from $2.46 billion in 2011 to $3.55 billion in 2012, $5.8 billion in 2013, $8.3 billion in 2014, and peaked at approximately $10.4 billion in 2015, reflecting a exceeding 40% over this period. This expansion was fueled by major deals, including the $8.7 billion acquisition of in 2013 and the $14.5 billion purchase of Salix Pharmaceuticals in 2015, which added high-margin , , and portfolios but also increased debt leverage to over 5x EBITDA by 2015. The growth trajectory reversed sharply starting in late 2015 amid controversies over channel stuffing via the Philidor Rx Services pharmacy network, which inflated short-term but led to returns and regulatory . Revenues fell 7% to $9.7 billion in 2016, followed by further declines to $8.7 billion in 2017 and $8.4 billion in , driven by divestitures of non-core assets (e.g., $221 million impact from and discontinuations in ), generic erosion on key drugs like Wellbutrin XL, and heightened pricing pressures from legislation and congressional investigations. This period of volatility exposed the model's risks: heavy dependence on a concentrated product mix (top products for over 40% of ) and limited , with same-store often lagging behind acquisition-driven gains. Post-2018, revenues stabilized in the $8-9 billion range through 2023 ($8.6 billion in 2019, $8.0 billion in 2020 amid disruptions, and $8.8 billion in 2023), reflecting cost-cutting, refinancing, and modest organic contributions from core segments like Xifaxan and Duobrii, though offset by ongoing expirations and litigation costs. A rebound to $9.63 billion in 2024 marked 10% reported growth, primarily from Bausch + Lomb's vision care strength and Solta Medical's aesthetic devices, though adjusted for and divestitures, underlying volatility persists due to high servicing (over $1 billion annually) and reliance on fewer than 20 products for the majority of sales.
YearRevenue ($ billions)YoY Change (%)
20112.46+124 (from 2010 est. $1.1B)
20123.55+44
20135.8+63
20148.3+43
201510.4+25
20169.7-7
20178.7-10
20188.4-4
20198.6+2
20208.0-7
20238.8+3 (est.)
20249.63+10

Debt accumulation, spin-offs, and recovery metrics

Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals, accumulated substantial debt through an aggressive acquisition strategy in the early 2010s, financing purchases such as , , and Salix Pharmaceuticals primarily with borrowed funds. By 2015, long-term exceeded $30 billion amid integration challenges and operational missteps following these deals. This buildup contributed to financial strain, exacerbated by pricing controversies and distribution issues, leading to downgrades and restructuring needs. To streamline operations and alleviate debt pressures, Bausch Health announced plans on August 6, 2020, to spin off its Bausch + Lomb eye health unit as an independent publicly traded entity, a process completed in May 2022. The separation allowed to secure its own credit facilities and focus on products, while Bausch Health retained an 88% ownership stake as of February 2025. Further spin-off initiatives followed, including filings in 2023 to separate Solta Medical () and Bausch Pharma (diversified portfolio), aiming to create three distinct public entities and unlock value for debt reduction. Recovery efforts have centered on through cash generation, asset sales, and debt exchanges, with net debt reduced by $670 million in 2023 via operational cash flows and cost controls. In July 2025, the company repaid approximately $900 million using cash on hand, targeting near-term maturities. Despite these steps, total debt stood at $21.74 billion as of June 2025, with a exceeding 14,000%, reflecting persistent leverage risks and challenges for $1.7 billion in 2025 secured bonds. agencies like Fitch maintain ratings at 'CCC', citing moderate debt paydown but vulnerability to revenue volatility in core products like XIFAXAN.

Recent quarterly results and projections (2023–2025)

In 2023, Bausch Health achieved consolidated revenues of $8.76 billion, marking an 8% increase from $8.12 billion in 2022, driven primarily by growth in its and segments. Fourth-quarter 2023 revenues totaled $2.41 billion, reflecting 10% reported growth year-over-year. The company reported consolidated revenues of $9.63 billion for full-year 2024, a 10% increase on a reported basis and 8% on an organic basis compared to 2023, with adjusted EBITDA rising 10% to $3.31 billion. Fourth-quarter 2024 revenues reached $2.56 billion, up 6% reported and 9% organically from the prior year's quarter. Into 2025, first-quarter revenues were $2.26 billion, a 5% reported increase and 6% over Q1 2024. Second-quarter 2025 revenues amounted to $2.53 billion, up 5% reported and 4% organically from $2.40 billion in Q2 2024, accompanied by adjusted EBITDA of $842 million (up 6%) and GAAP net income of $148 million.
PeriodConsolidated RevenueYear-over-Year Change (Reported)
FY 2023$8.76 billion+8% from FY 2022
FY 2024$9.63 billion+10% from FY 2023
Q1 2025$2.26 billion+5% from Q1 2024
Q2 2025$2.53 billion+5% from Q2 2024
Bausch Health raised its full-year 2025 consolidated revenue guidance to $10.0 billion to $10.25 billion in August 2025, implying approximately 4% to 6% growth over 2024, alongside reaffirmed adjusted EBITDA expectations reflecting operational efficiencies and segment expansions. This outlook incorporates strategic moves such as debt reduction exceeding $900 million post-Q2 2025 and the planned acquisition of DURECT Corporation to bolster assets.

Leadership and Governance

Key executives and their tenures

Thomas J. Appio has served as and Director since May 2022. Jean-Jacques Charhon has been Executive and since August 19, 2024. Seana Carson has held the position of Executive and since May 2022, having joined the company in November 2006. Mirza Dautbegovic has been Executive and since at least May 2022, after joining Bausch Health in 2017 as of . Jonathan Sadeh has served as Executive , , and Head of Research & Development since December 2, 2024. Aimee J. Lenar has been Executive , U.S. Pharma, since July 15, 2024.
ExecutiveRoleTenure Start
Thomas J. AppioMay 2022
Jean-Jacques CharhonExecutive VP & August 19, 2024
Seana CarsonExecutive VP & May 2022 (joined company: November 2006)
Mirza DautbegovicExecutive VP & COOMay 2022 (joined company: 2017)
Jonathan SadehExecutive VP, CMO & Head of R&DDecember 2, 2024
Aimee J. LenarExecutive VP, U.S. PharmaJuly 15, 2024

Board composition and activist investor influences

As of October 2025, the Bausch Health board of directors comprises ten members, a majority of whom are independent directors with backgrounds in pharmaceuticals, finance, and governance. John A. Paulson serves as chairperson, having rejoined the board after prior service from 2017 to 2022; he is the president and portfolio manager of Paulson & Co. Inc., a hedge fund focused on value investments. Thomas J. Appio, the company's CEO since June 2022, holds an executive seat. Recent additions include Michael Goettler, former CEO of Viatris Inc., and Sandra S. Leung, a governance expert with prior roles at Pfizer Inc. and Gilead Sciences Inc., both appointed effective July 22, 2025, to bring specialized industry expertise amid strategic reviews. Other key independents include Christian A. Garcia, chair of the audit committee with financial oversight experience, and Sarah B. Kavanagh, involved in compensation matters. Activist investors have significantly shaped the board's composition through nomination agreements and share accumulations. In February 2021, Bausch Health reached an agreement with Carl C. Icahn, granting his affiliates two board seats—Brett M. Icahn and Steven D. Miller—expiring at the 2022 annual meeting but extended via ongoing pacts tied to ownership thresholds. Icahn's influence peaked in April 2025 when his group disclosed a 34% economic interest (9.4% direct shares plus swaps), prompting the board to adopt a (poison pill) to deter control shifts without negotiation; shareholders ratified this in October 2025. By August 15, 2025, the Icahn Group's stake fell below triggering levels after selling 34.7 million shares to Paulson & Co. affiliates, terminating the nomination agreement and leading to the resignations of Brett M. Icahn and Steven D. Miller. This shifted dominance to John Paulson, whose firm increased its holding to 19.13% of outstanding shares, positioning him to advocate for asset monetization and debt reduction without Icahn's counterpressure. Paulson's role as chairperson reflects his long-term push for shareholder value, including prior campaigns emphasizing spin-offs and operational efficiencies, contrasting Icahn's more confrontational tactics that had stalled strategic initiatives. These dynamics underscore activist-driven governance reforms, with board changes prioritizing aligned investors over hostile accumulators.

References

  1. https://finance.yahoo.com/quote/BHC/profile/
  2. https://www.globaldata.com/company-profile/bausch-health-companies-inc/
  3. https://www.bauschhealth.com/about-us/
  4. https://www.bloomberg.com/news/articles/2017-03-15/how-to-lose-4-billion-bill-ackman-s-long-ride-down-on-valeant
  5. https://www.sec.gov/newsroom/press-releases/2020-169
  6. https://www.bloomberg.com/gadfly/articles/2015-11-11/valeant-controversy-puts-platform-model-in-the-spotlight
  7. https://www.bloomberg.com/news/articles/2017-05-02/valeant-ponders-a-name-change-to-try-and-escape-past-reputation
  8. https://www.reuters.com/legal/us-supreme-court-declines-hear-patent-dispute-over-bausch-blockbuster-diarrhea-2024-11-18/
  9. https://www.latimes.com/archives/la-xpm-2002-jun-13-fi-icn13-story.html
  10. https://www.bloomberg.com/news/articles/1996-06-30/milan-panic-may-be-starting-to-sweat
  11. https://www.nytimes.com/2002/06/13/business/company-news-founder-of-icn-pharmaceuticals-to-retire-as-chief.html
  12. https://nymag.com/intelligencer/2016/01/valeant-wall-st-darling-to-pariah.html
  13. https://www.latimes.com/archives/la-xpm-2010-jun-22-la-fi-valeant-20100622-story.html
  14. https://www.wsj.com/articles/SB106859059793942500
  15. https://www.latimes.com/archives/la-xpm-2003-nov-12-fi-icn12-story.html
  16. https://www.1stoncology.com/blog/icn-pharmaceuticals-inc-changes-its-name-to-valeant-pharmaceuticals-international/
  17. https://www.pharmexec.com/view/valeant-pharmaceuticals-soldiering
  18. http://media.corporate-ir.net/media_files/irol/11/119269/reports/AnnualReport_10KFINAL.pdf
  19. https://www.reuters.com/article/world/europe/deals-and-doubts-mark-valeants-acquisition-history-idUSL1N12N1PL/
  20. https://www.sec.gov/Archives/edgar/data/885590/000104746911001555/a2202280z10-k.htm
  21. https://financialpost.com/investing/market-moves/how-valeant-got-here-a-timeline-of-takeovers
  22. https://www.bloomberg.com/news/articles/2015-10-26/valeant-ceo-s-outsider-roots-spun-market-gold-until-they-didn-t
  23. https://www.reuters.com/article/business/timeline-shakeup-at-valeant-as-longtime-ceo-pearson-leaving-idUSKCN0WN28X/
  24. https://www.sec.gov/Archives/edgar/data/885590/000088559017000015/valeant2016form10-k.htm
  25. https://www.theglobeandmail.com/report-on-business/rob-magazine/inside-story-valeant-pharmaceuticals-fall/article34432530/
  26. https://dealbook.nytimes.com/2014/04/21/valeants-history-of-deal-making/
  27. https://www.bloomberg.com/news/articles/2015-10-21/valeant-s-pharma-formula-deals-drugs-and-lots-of-questions
  28. https://www.vanityfair.com/news/2016/06/the-valeant-meltdown-and-wall-streets-major-drug-problem
  29. https://www.biospace.com/valeant-to-change-its-name-to-bausch-health-companies-reports-loss-in-first-quarter
  30. https://www.kellogg.northwestern.edu/news_articles/profiles/alumni/joseph-papa.aspx/
  31. https://insights.citeline.com/SC065366/Valeants-Papa-Lays-Out-Plan-For-Turnaround/
  32. http://ir.valeant.com/~/media/Files/V/Valeant-IR/reports-and-presentations/q4-fy2016-vrx-02282017-v1.pdf
  33. https://www.nasdaq.com/articles/valeant-inks-deal-to-divest-inova-pharmaceuticals-for-%24930m-2017-06-12
  34. https://www.sec.gov/Archives/edgar/data/885590/000088559018000029/valeantq12018.htm
  35. https://www.bloomberg.com/news/articles/2018-01-10/valeant-ceo-in-midst-of-turnaround-opportunity-of-a-lifetime
  36. https://www.cnbc.com/2017/01/10/valeant-to-pay-down-5-billion-in-18-months-to-reduce-debt-ceo-joseph-papa-says.html
  37. https://www.theglobeandmail.com/business/article-bausch-health-tries-to-balance-debt-reduction-and-and-acquisitions-as/
  38. https://www.prnewswire.com/news-releases/valeant-will-become-bausch-health-companies-inc-300644091.html
  39. https://www.nytimes.com/2018/05/08/health/valeant-name-bausch-drugs.html
  40. https://ir.bauschhealth.com/news-releases/2018/07-13-2018
  41. https://halifax.citynews.ca/2019/01/07/bausch-health-formerly-valeant-predicts-revenue-growth-as-debt-load-lessens/
  42. https://www.prnewswire.com/news-releases/bausch-health-to-reduce-debt-by-275-million-301198803.html
  43. https://www.fiercebiotech.com/medtech/bausch-health-s-aesthetics-devicemaker-solta-to-go-public-debt-reduction-scheme
  44. https://ir.bauschhealth.com/news-releases/2022/06-23-2022-215444158
  45. https://www.visionmonday.com/people/moves/article/bausch-lomb-begins-search-for-successor-to-ceo-joseph-papa-who-also-steps-down-as-bls-board-chairman
  46. https://ir.bauschhealth.com/news-releases/2022/05-06-2022-170831954
  47. https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/20220510-1q22-earnings-presentation.pdf
  48. https://ir.bausch.com/press-releases/bausch-health-and-bausch-lomb-corporation-announce-closing-initial-public-offering
  49. https://www.sec.gov/Archives/edgar/data/885590/000114036123017061/ny20007033x3_ars.pdf
  50. https://www.fitchratings.com/research/corporate-finance/fitch-downgrades-bausch-health-co-idr-to-c-on-proposed-distressed-debt-exchange-31-08-2022
  51. https://ir.bauschhealth.com/news-releases/2023/08-03-2023
  52. https://companiesmarketcap.com/bausch-health/total-debt/
  53. https://ir.bauschhealth.com/news-releases/2025/07-28-2025
  54. https://know.creditsights.com/webinars/inside-bausch-health-big-move-new-debt-old-risks/
  55. https://ir.bauschhealth.com/news-releases/2025/07-30-2025
  56. https://boardsi.com/bausch-health-expands-board-what-the-appointments-of-michael-goettler-and-sandra-leung-mean-for-corporate-leadership/
  57. https://340breport.com/bausch-health-removes-high-cost-liver-disease-gi-treatment-many-other-drugs-from-340b-and-medicaid-rebate-programs/
  58. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhc/bausch-health-companies/health
  59. https://www.newyorker.com/business/currency/valeant-why-moneyball-failed-in-the-pharmaceutical-industry
  60. https://www.congress.gov/114/chrg/CHRG-114shrg48176/CHRG-114shrg48176.pdf
  61. https://www.reuters.com/article/business/drugmaker-valeant-to-buy-bausch-lomb-for-87-billion-idUSBRE94Q09V/
  62. https://ir.bauschhealth.com/news-releases/archive/2015/22-02-2015
  63. https://www.genengnews.com/news/valeant-acquiring-bausch-lomb-for-8-7b/
  64. https://www.genengnews.com/news/valeant-and-biovail-merge-to-achieve-cost-savings-of-175m-per-year/
  65. https://ir.bauschhealth.com/news-releases/2019/03-06-2019-140049498
  66. https://www.pharmexec.com/view/bausch-health-acquires-durect-corporation-deal-413-million
  67. https://www.wsj.com/articles/bid-for-allergan-puts-valeants-research-and-development-cuts-under-scrutiny-1402443053
  68. https://www.propublica.org/article/does-valeants-cost-cutting-go-too-far
  69. https://d3.harvard.edu/platform-rctom/submission/valeant-pharmaceuticals-disruption-or-destruction/
  70. https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/2023-annual-report.pdf
  71. https://www.sec.gov/Archives/edgar/data/885590/000088559025000007/bhc-20241231.htm
  72. https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/q4-and-fy-2023-earnings-presentation.pdf
  73. https://www.ainvest.com/news/bausch-health-strategic-turnaround-unlocking-debt-reduction-hepatology-innovation-2509/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC4942235/
  75. https://www.proxsysrx.com/2025/10/22/bausch-has-pulled-its-drug-catalog-from-the-340b-program/
  76. https://www.linkedin.com/posts/stevenzielinski_bausch-health-removes-high-cost-liver-disease-activity-7376375484978208768-ghLQ
  77. https://www.340bhealth.org/newsroom/statement-on-bausch-health-restricting-340b-discounts-through-community-based-pharmacies/
  78. https://www.fiercehealthcare.com/providers/drugmaker-340b-contract-pharmacy-restrictions-continue-bausch-health
  79. https://www.bauschhealth.com/products/patient-assistance-programs/
  80. https://www.bauschhealth.com/siteassets/PDF/BauschHealth-CSR-Report.pdf
  81. https://dcfmodeling.com/products/bhc-marketing-mix
  82. https://www.hrsa.gov/sites/default/files/hrsa/opa/bausch-health-covered-entity.pdf
  83. https://cio.economictimes.indiatimes.com/news/strategy-and-management/how-bausch-lomb-adopted-direct-to-consumer-approach/80699538
  84. https://www.transparently.ai/blog/the-valeant-scandal
  85. https://www.ir.bauschhealth.com/tools/viewpdf.aspx?page=%257BDF9C622C-6370-4C64-ADF7-6A02E363386F%257D
  86. https://ir.bauschhealth.com/tools/viewpdf.aspx?page=%257B2C13B7C6-0AFD-45A0-9D9D-67CAA81630DD%257D
  87. https://www.rksllp.com/bulletin/bausch-lomb-spin-off
  88. https://ir.bauschhealth.com/news-releases/2025/03-19-2025a
  89. https://seekingalpha.com/article/4822122-bausch-health-repricing-continues-as-deleveraging-gains-traction
  90. https://www.investing.com/news/transcripts/earnings-call-transcript-bausch-health-q2-2025-sees-steady-growth-strategic-moves-93CH-4287491
  91. https://www.fitchratings.com/research/corporate-finance/fitch-affirms-withdraws-bausch-health-ratings-09-05-2025
  92. https://www.ainvest.com/news/bausch-health-strategic-moves-debt-reduction-pipeline-expansion-drivers-shareholder-2025-2507/
  93. https://seekingalpha.com/article/4795065-bausch-health-stock-repricing-potential-driven-by-deleveraging
  94. https://www.ainvest.com/news/bausch-lomb-post-icahn-restructuring-era-governance-shareholder-2508/
  95. https://businessabc.net/wiki/valeant-pharmaceuticals-international
  96. https://www.bizjournals.com/losangeles/stories/2005/01/31/daily31.html
  97. https://www.thepharmaletter.com/valeant-to-acquire-xcel-pharma
  98. https://www.massdevice.com/valeant-closes-250m-acquisition-solta-medical/
  99. https://ir.bauschhealth.com/news-releases/2018/05-08-2018-120255538
  100. https://ir.bauschhealth.com/news-releases/2019/02-20-2019-120131096
  101. https://www.biospace.com/bausch-health-announces-second-quarter-2024-results
  102. https://ir.bauschhealth.com/news-releases/2025/07-29-2025
  103. https://ir.bauschhealth.com/news-releases/2025/09-11-2025
  104. https://www.prnewswire.com/news-releases/valeant-pharmaceuticals-international-inc-to-acquire-bausch--lomb-for-87-billion-209046651.html
  105. https://pi.bausch.com/globalassets/pdf/news-archive/bauschhealthpdf/27-05-2013.pdf
  106. https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/acquisition-of-bausch-and-lomb.pdf
  107. https://www.bauschhealth.com/products/eye-health/
  108. https://www.healio.com/news/ophthalmology/20220114/bausch-excited-about-eye-health-business-ahead-of-ipo
  109. https://ir.bauschhealth.com/news-releases/2023/09-29-2023
  110. https://ir.bausch.com/press-releases/bausch-lomb-announces-second-quarter-2025-results
  111. https://ir.bauschhealth.com/news-releases/2022/04-28-2022-144043985
  112. https://ir.bauschhealth.com/news-releases/2025/02-06-2025
  113. https://ir.bausch.com/press-releases/bausch-lomb-provides-update-potential-sale
  114. https://www.bloomberg.com/news/articles/2025-02-06/bausch-lomb-sinks-after-disclosing-it-won-t-go-private-now
  115. https://ir.bauschhealth.com/news-releases/2025/02-19-2025
  116. https://ir.bausch.com/press-releases/bausch-lomb-announces-fourth-quarter-and-full-year-2024-results-provides-2025
  117. https://ir.bausch.com/sites/bauschhealth-ir/files/2025-07/bausch-lomb-2q25-earnings-presentation.pdf
  118. https://www.bauschhealth.com/products/dermatology-products-aesthetics-devices/
  119. https://www.bauschhealth.com/products/us-product-list/
  120. https://www.bauschhealth.com/products/gastrointestinal/
  121. https://synapse.patsnap.com/article/what-are-the-top-selling-drugs-of-bausch-health
  122. https://www.prnewswire.com/news-releases/bausch-health-enters-into-definitive-stalking-horse-agreement-to-acquire-substantially-all-the-assets-of-synergy-pharmaceuticals-inc-300764140.html
  123. https://www.bauschhealth.com/products/generics-neurology-and-other/
  124. https://pi.bauschhealth.com/
  125. https://ir.bauschhealth.com/
  126. https://www.relistor.com/
  127. https://ir.bauschhealth.com/news-releases/2021/12-22-2021-120114539
  128. https://pmc.ncbi.nlm.nih.gov/articles/PMC10391063/
  129. https://ir.bauschhealth.com/news-releases/2024/03-06-2024
  130. https://www.bauschhealth.com/r-d/our-pipeline/
  131. https://ir.bauschhealth.com/news-releases/2024/06-14-2024
  132. https://www.bauschhealth.com/siteassets/pdf/bauschhealth_rd_pipeline_sept_2025.pdf
  133. https://www.businessinsider.com/valeant-not-profitable-as-normal-drug-co-2016-3
  134. https://www.reuters.com/article/business/bausch-health-three-former-executives-agree-to-penalties-to-resolve-us-sec-ch-idUSKCN24W316/
  135. https://www.nbcnews.com/health/health-news/valeant-ceo-faces-hostile-congress-regrets-drug-price-hikes-n563386
  136. https://www.bbc.com/news/business-36117915
  137. https://www.aging.senate.gov/imo/media/doc/Drug%2520Pricing%2520Report.pdf
  138. https://firstwordpharma.com/story/3216746
  139. https://www.forbes.com/sites/jimosman/2021/04/28/a-buried-scandal-shedding-of-assets-and-forthcoming-spinoff-means-substantial-upside-for-bausch-health/
  140. https://www.fiercepharma.com/pharma/bausch-even-after-shedding-valeant-name-still-leans-price-hikes-analyst
  141. https://www.marketwatch.com/story/valeant-is-back-on-to-its-old-drug-pricing-ways-2018-06-29
  142. https://www.fiercepharma.com/pharma/bausch-pays-whopping-300m-to-settle-antitrust-dispute-for-type-2-diabetes-drug-glumetza
  143. https://www.gurufocus.com/news/3117874/bausch-health-bhc-and-teva-accused-of-antitrust-violations-over-xifaxan
  144. https://www.fiercepharma.com/pharma/bausch-faces-legal-hold-doj-marketing-probe-report
  145. https://www.biopharmadive.com/news/bausch-sec-settlement-valeant-philidor/582780/
  146. https://www.cbc.ca/news/business/valeant-pharmaceuticals-pershing-1.4023893
  147. https://www.sec.gov/files/litigation/admin/2020/33-10809.pdf
  148. https://www.biopharmadive.com/news/valeant-severs-ties-with-controversial-specialty-pharma-after-mass-pbm-exod/408329/
  149. https://www.biospace.com/valeant-severs-ties-with-controversial-specialty-pharmacy-b-philidor-b-which-plans-to-shutter-its-doors
  150. https://ir.bauschhealth.com/news-releases/2020/07-31-2020-214355059
  151. https://www.reuters.com/article/business/ex-valeant-philidor-executives-convicted-of-kickback-scheme-idUSKCN1IN23G/
  152. https://www.cohenmilstein.com/valeant-pay-23m-end-secret-pharmacy-rico-claims-law360/
  153. https://www.sec.gov/enforcement-litigation/distributions-harmed-investors/matters-valeant-pharmaceuticals-international-inc-nka-bausch-health-companies-inc-j-michael-pearson
  154. https://www.issgovernance.com/valeant-pharmaceuticals-settles-stock-drop-litigation-for-1-billion/
  155. https://www.rgrdlaw.com/cases-in-re-valeant-pharms-intl-inc-sec.html
  156. https://ir.bauschhealth.com/news-releases/2020/08-05-2020-120334228
  157. https://content.next.westlaw.com/practical-law/document/I8a0a5afaeb2011efa644be47958a88c4/Bausch-Health-beats-investor-suit-over-Valeant-scandal?viewType=FullText&transitionType=Default&contextData=%28sc.Default%29
  158. https://www.reuters.com/article/world/us/convictions-of-ex-valeant-and-philidor-executives-are-upheld-payouts-reduced-idUSKBN1XA21X/
  159. https://www.valeantsecuritiessettlement.com/
  160. https://www.valeantsecuritiessettlement.ca/
  161. https://www.cohenmilstein.com/case-study/re-valeant-pharmaceuticals-international-inc-third-party-payor-litigation/
  162. https://www.reuters.com/business/healthcare-pharmaceuticals/bausch-pay-300-mln-antitrust-suit-over-diabetes-drug-2021-09-09/
  163. https://www.cbo.gov/publication/57126
  164. https://aspe.hhs.gov/reports/pharmaceutical-pricing-practices-utilization-costs-meeting-summary
  165. https://www.commonwealthfund.org/publications/issue-briefs/2022/jul/impact-pharmaceutical-wholesalers-drug-spending
  166. https://www.ncbi.nlm.nih.gov/books/NBK570140/
  167. https://www.bmj.com/content/368/bmj.l4627
  168. https://www.ir.bauschhealth.com/tools/viewpdf.aspx?page=%257B536B06DB-FF41-467A-95E4-25F35ED5100F%257D
  169. https://pi.bausch.com/globalassets/pdf/news-archive/bauschhealthpdf/27-02-2014.pdf
  170. http://d1lge852tjjqow.cloudfront.net/CIK-0000885590/04b1aea1-4197-484b-9d0c-e4489f52839f.pdf
  171. https://www.sec.gov/Archives/edgar/data/885590/000088559016000101/valeant2015form10-k.htm
  172. https://companiesmarketcap.com/bausch-health/revenue/
  173. https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/2015-10k.pdf
  174. https://ir.bauschhealth.com/news-releases/2021/02-24-2021-115929880
  175. https://www.macrotrends.net/stocks/charts/BHC/bausch-health-cos/revenue
  176. https://seekingalpha.com/article/4655100-bausch-health-20bn-debt-mighty-elephant-in-the-room
  177. https://ir.bauschhealth.com/news-releases/2020/08-06-2020-115906716
  178. https://ir.bausch.com/press-releases/bausch-lomb-provides-leadership-update
  179. https://stockspinoffinvesting.com/spin-offs/bausch-health-spin-off-notes/
  180. https://finance.yahoo.com/quote/BHC/key-statistics/
  181. https://www.fitchratings.com/research/corporate-finance/fitch-affirms-bausch-health-idr-at-ccc-11-09-2024
  182. https://ir.bauschhealth.com/news-releases/2024/02-22-2024
  183. https://firstwordpharma.com/story/5955965
  184. https://www.webull.ca/news-detail/13321712547234816
  185. https://ir.bauschhealth.com/corporate-governance/board-of-directors
  186. https://ir.bauschhealth.com/news-releases/2024/07-19-2024
  187. https://www.sec.gov/Archives/edgar/data/885590/000114036125011851/ny20039462x1_def14a.htm
  188. https://www.bauschhealth.com/about-us/executive-leadership-team/
  189. https://ir.bauschhealth.com/news-releases/2024/12-02-2024
  190. https://ir.bauschhealth.com/news-releases/2025/07-24-2025
  191. https://ir.bauschhealth.com/corporate-governance/committees
  192. https://ir.bauschhealth.com/news-releases/2021/02-24-2021-114524123
  193. https://www.reuters.com/sustainability/sustainable-finance-reporting/bausch-health-says-carl-icahn-has-exposure-about-34-companys-shares-2025-04-22/
  194. https://ir.bauschhealth.com/news-releases/2025/08-15-2025
  195. https://www.stocktitan.net/news/BHC/bausch-health-announces-increase-in-shareholding-by-its-chairperson-49o0u9ct46nw.html
Add your contribution
Related Hubs
User Avatar
No comments yet.